INMUNOTERAPIA EN CÁNCER GÁSTRICO Y DE LA UGE: DÓNDE ESTAMOS? Maria Alsina Maqueda, MD, PhD Hospital Universitario Vall d Hebron, Barcelona
|
|
- Ezra Parrish
- 6 years ago
- Views:
Transcription
1 INMUNOTERAPIA EN CÁNCER GÁSTRICO Y DE LA UGE: DÓNDE ESTAMOS? Maria Alsina Maqueda, MD, PhD Hospital Universitario Vall d Hebron, Barcelona
2 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
3 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
4 Tumors are complex systems Successful growth of tumors and metastasis is not determined solely by genetic alterations in tumor cells, but also by the advantage that such mutations confer in the environment. Tumor formation involves the co-evolution of malignant cells together with extracellular matrix, tumor vasculature and immune cells. Tumor Antigen Transport Lymphocyte trafficking Junttila Nature 213
5 Hanahan & Weinberg Cell 211 Acquired capacities of cancer: phenotype Aerobic glycolysis inhibitors EGFR inhibitors Deregulating cellular energetics Sustaining proliferative signaling Inhibitors of VEGF signaling Inducing angiogenesis Evading growth suppressors Cyclin-dependent kinase inhibitors Proapoptotic BH3 mimetics Resisting cell death Avoiding immune destruction Immunotherapy PARP inhibitors Genome instability mutation Activating invasion & metastasis Tumorpromoting inflammation Enabling replicative immortality Telomerase inhibitors Inhibitors of HGF/c-Met Selective antiinflammatory drugs
6 Key aspects of the Immune System The immune system recognises and destroys tumor cells Key features of the immune response: Specificity Memory Adaptability Hanahan & Weinberg Cell 211; Dunn Nat Rev Immunol 26 Swann & Smyth J Clin Invest 27; Prendergast Oncogene 28; Mapara & Sykes J Clin Oncol 24
7 Overall survival Immunotherapy has reset survival expectations 1. Ipilimumab was the first immune checkpoint inhibitor to demonstrate clinical benefit in stage IV melanoma patients.8 Pooled OS data for 1,861 patients from 1 prospective and two retrospective studies Median OS, months: 9.5 months (95% CI 9. 1.) year OS rate: 21% (95% CI 2 22).2. No at risk: Ipilimumab Ipilimumab Censored Months Schadendorf J Clin Oncol 215
8 Chen & Mellman Immunity 213 The immune cycle in cancer 3. Priming and activation Anti-PD1 Anti-PDL1 Anti-CTLA-4 Anti-CD137 (agonist) Anti-OX4 (agonist) Anti-CD27 (agonist) IL-2 IL Trafficking of T cells to tumors 5. Infiltration of T cells into tumors 2. Cancer antigen presentation Vaccines IFN-α GM-CSF Anti-CD4 (agonist) TLR agonist Lymph node Blood vessel Tumor Anti-VEGF/VEGFR 6. Recognition of cancer cells by T cells CARs 1. Release of cancer cell antigens Chemotherapy Radiation therapy Targeted therapy 7. Killing of cancer cells Anti-PDL1 Anti-PD1 IDO inhibitors
9 Chen & Mellman Immunity 213 The immune cycle in cancer 3. Priming and activation Anti-PD1 Anti-PDL1 Anti-CTLA-4 Anti-CD137 (agonist) Anti-OX4 (agonist) Anti-CD27 (agonist) IL-2 IL Trafficking of T cells to tumors 5. Infiltration of T cells into tumors 2. Cancer antigen presentation Vaccines IFN-α GM-CSF Anti-CD4 (agonist) TLR agonist Lymph node Blood vessel Tumor Anti-VEGF/VEGFR 6. Recognition of cancer cells by T cells CARs 1. Release of cancer cell antigens Chemotherapy Radiation therapy Targeted therapy 7. Killing of cancer cells Anti-PDL1 Anti-PD1 IDO inhibitors
10 Amorena Science 1978, Mueller J Immunol 1989, Walunas Immunity 1994, Krummel J Exp Med 1995, Dong Nat Med 22; Keir Annu. Rev. Immunol. 28 T cell activation requirements 1. Antigen presentation MHC complex 2. Co-stimulatory signal B7 CD28 3. Cytokines 4. Inhibitory signal B7 CTLA4 PDL-1 PD-1
11 The immune checkpoint targetable receptors/ligands T cell targets for modulating activity Activating Receptors Inhibitory Receptors CD28 OX4 GITR CD137 CD27 HVEM T cell CTLA-4 PD-1 TIM-3 BTLA VISTA LAG-3 Agonistic Antibodies T cell stimulation Blocking Antibodies Mellman Nature 211
12 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
13 Rhabdoid tumour Ewing sarcoma Thyroid Acute myeloid leukaemia Medulloblastoma Carcinoid Neuroblastoma Prostatre Chronic lymphocytic leukaemia Low-grade glioma Breast Pancreas Multiple myeloma Kidney clear cell Kidney papillary cell Ovarian Glioblastoma multiforme Cervical Diffuse large B-cell lymphoma Head and neck Colorectal Esophageal adenocarcinoma Stomach Bladder Lung adenocarcinoma Lung squamous cell carcinoma Melanoma Somatic mutation frequency (/Mb) Frequency of genetic somatic mutations in cancer No at Risk C T C A C G T C T A T G Altered proteins contain new epitopes for immune recognition, providing a common denominator for cancer immunotherapy Lawrence Nature 213
14 5% 9% 22% 2% TCGA Nature 214
15 TILs are predictive of overall survival in GC Pooled OS data for 22 patients with gastric cancer surgically resected Lee Br J Cancer 28
16 Analysis of PDL1 expression and T cells infiltration 114 GC pts PD-L1, CD3 and CD8 Immune cells (IC) PD-L1 74.9% 37.8% Tumor cells (TC) PD-L1 High (TC and IC) Better OS CD3+ High and CD8+ High Better OS Close relationship between CD3+, CD8+ cell density and PDL1 expression (TC and IC) Patients with higher CD8 and CD3 T cell densities also have higher PD-L1 expression, indicating an adaptive immune resistance mechanism may be occurring Xing ASCO GI 217
17 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
18 First evidence of efficacy Anti-PD1 Pembrolizumab: KEYNOTE 12 1, KEYNOTE 59 2 Nivolumab: Checkmate 32 3, ONO-4538/BMS Anti-PDL1 Avelumab: JAVELIN Japanese 5 Others Ipilimumab: Maintenance 6 New promises (other immune checkpoints and combined strategies) 1. Muro Lancet Oncol 216, 2. Fuchs ASCO 216, 3. Janjigian ASCO 216, 4. Kang ASCO GI 217; 5. Chung ASCO 216; 6. Moehler ASCO 216
19 KEYNOTE-12: Gastric Cancer Cohort Complete Response Discontinuation Permitted Patients Recurrent or metastatic adenocarcinoma of the stomach or GEJ ECOG PS -1 PD-L1 positive tumor a No active brain metastases Pembrolizumab 1 mg/kg Q2W Partial Response or Stable Disease Treat for 24 months or until progression or intolerable toxicity Confirmed Progressive Disease Discontinue Screening: 65 of 162 (4%) patients assessed for PD-L1 expression had PD-L1-positive tumors Patients: 19 patients from Asia and 2 patients from the rest of the world Treatment: 1 mg/kg IV Q2W Response assessment: Performed every 8 weeks per RECIST v1.1 by central radiology review a Assessed in archival tumor samples using a prototype IHC assay (22C3 antibody). Positivity defined as PD-L1 staining in stroma or 1% of tumor cells. Muro Lancet Oncol 216
20 Best Overall Response, RECIST v1.1 Muro Lancet Oncol 216
21 Change From Bassline, % Change From Baseline in Target Lesions Change From Baseline, % Maximum Change Change Over Time 15 1 Asia Asia Rest of world 125 Rest of world % of patients experienced a decrease from baseline Time, weeks a Only patients with measurable disease per RECIST v1.1 by central review at baseline and at least 1 postbaseline tumor assessment were included (n = 32). Analysis cutoff date: March 23, 215. Muro Lancet Oncol 216
22 Overall Survival, % Kaplan-Meier Estimates of Survival 1 OS OS (ITT) 6-months OS rate: 66% Median OS: 11m (95% CI, 5.7-NR) 1 Asia Rest of world Time, months n at risk Asia ROW Median response duration 4w (2+ to 48+) Analysis cutoff date: March 23, 215. Muro Lancet Oncol 216
23 Ph 2 Study in 1 st Line GC/GEJ pts KEYNOTE 59 Pembro 2 mg + 5-FU 8 mg/m 2 (or capecitabine 1 mg/m 2 in Japan) + cisplatin 8 mg/m 2 Q3W for 6 cycles Pembro + 5-FU (or capecitabine) for up to 2y 18 patients treated, median follow-up 5.5 m No treatment-related deaths 1 pt (6%) discontinued treatment Stomatitis unrelated to pembro or chemotherapy. 7 pts (39%) G1-2 AEs attributed to pembro Diarrhea, dysgeusia, hyperthyroidism, nausea (n = 2 each) 8 pts (44%) experienced G1-2 AEs of special interest, regardless of attribution by investigator Hyperthyroidism, hypothyroidism, infusion-related reaction, pruritus, vasculitis. The combination of pembro, cisplatin, and 5-FU has a manageable safety profile as first-line therapy in patients with advanced GC Fuchs ASCO 216
24 Checkmate 32: Nivolumab +/- Ipi Phase I/II with a GC/GEJ/EC cohort (16 pts) Irrespectively of PD-L1 status 3 different schemes of treatment Nivo 3 mg/kg Q2W Nivo 1 mg/kg + ipi 3 mg/kg Nivo 3 mg/kg + ipi 1 mg/kg Q3W x 4 cycles Nivo 3 mg/kg Q2W ORR (1 st End Point) Janjigian ASCO 216
25 Checkmate 32: Nivolumab +/- Ipi 12% of pts stopped therapy due to treatment toxicity Treatment-related serious AEs of any grade and Grade 3-4 occurred in 1% and 5% (N3), 43% and 35% (N1+I3), and 23% and 15% (N3+I1) of pts 1 Grade 5 tumor lysis syndrome (N3+I1) N3 N1+I3 N3+I1 ORR 14% 26% 1% mos (m) (95% CI) 5. ( ) 6.9 (3.6 NA) 4.8 (3. 9.1) Janjigian ASCO 216
26 Nivolumab (ONO-4538/BMS ) as Salvage Treatment After Second- or Later-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer (AGC): A Double-Blinded, Randomized, Phase 3 Trial Key eligibility criteria: Age 2 years Unresectable advanced or recurrent gastric or gastroesophageal junction cancer Histologically confirmed adenocarcinoma Prior treatment with 2 regimens and refractory to/intolerant of standard therapy ECOG PS of or 1 R 2:1 Nivolumab 3 mg/kg IV Q2W Stratification based on: Country (Japan vs Korea vs Taiwan) ECOG PS ( vs 1) Number of organs with metastases (< 2 vs 2) Placebo Primary endpoint: OS Secondary endpoints: Efficacy (PFS, BOR, ORR, TTR, DOR, DCR) Safety Exploratory endpoint: Biomarkers Patients were permitted to continue treatment beyond initial RECIST v1.1 defined disease progression, as assessed by the investigator, if receiving clinical benefit and tolerating study drug 493 patients randomized from 49 centers of Japan, Korea and Taiwan (Nov-214 Febr-216) Kang ASCO GI 217
27 Probability of Survival (%) Overall Survival At risk: Nivolumab 33 Placebo Patients, n 1 12 Time (months) Events, n Median OS [95% CI], months Hazard ratio,.63 (95% CI,.5.78) P < Month OS Rate [95% CI], % Nivolumab [ ] 26.6 [ ] Placebo [ ] 1.9 [ ] 22 Kang ASCO GI 217
28 RECIST Response and Disease Control ORR, n (%) [95% CI] P value BOR, n (%) Complete response Partial response Stable disease Progressive disease DCR, n (%) [95% CI] P value Nivolumab 3 mg/kg (n = 268) 3 (11.2) [ ] <.1 3 (11.2) 78 (29.1) 124 (46.3) 18 (4.3) [ ].36 Placebo (n = 131) [ 2.8] 33 (25.2) 79 (6.3) 33 (25.2) [ ] Median TTR (range), months 1.61 (1.4 7.) Median DOR, months [95% CI] 9.53 [ ] Kang ASCO GI 217
29 Adverse Event Summary Patients, n (%) AEs Any Serious AEs AEs leading to discontinuation AEs leading to dose delay Nivolumab 3 mg/kg (n = 33) Placebo (n = 161) Any Grade Grade 3/4 Any Grade Grade 3/4 3 (9.9) 131 (39.7) 23 ( 7.) 63 (19.1) 137 (41.5) 91 (27.6) 13 ( 3.9) 4 (12.1) 135 (83.9) 75 (46.6) 12 ( 7.5) 27 (16.8) AEs leading to death 35 (1.6) 25 (15.5) 63 (39.1) 47 (29.2) 9 ( 5.6) 17 (1.6) TRAEs Any Serious TRAEs TRAEs leading to discontinuation TRAEs leading to dose delay 141 (42.7) 33 (1.) 9 ( 2.7) 25 ( 7.6) 34 (1.3) 21 ( 6.4) 4 ( 1.2) 14 ( 4.2) 43 (26.7) 8 ( 5.) 4 ( 2.5) 2 ( 1.2) TRAEs leading to death 5 (1.5) 2 (1.2) 7 (4.3) 4 (2.5) 3 (1.9) 1 (.6) AE, adverse event; TRAE, treatment-related adverse event. Kang ASCO GI 217
30 Treatment-Related Adverse Events Patients, n (%) Nivolumab 3 mg/kg (n = 33) Placebo (n = 161) Any Grade Grade 3/4 Any Grade Grade 3/4 Any TRAE 141 (42.7) 34 (1.3) 43 (26.7) 7 (4.3) TRAEs in > 2% of patients treated with nivolumab Pruritus Diarrhea Rash Fatigue Decreased appetite Nausea Malaise AST increased Hypothyroidism Pyrexia ALT increased 3 (9.1) 23 (7.) 19 (5.8) 18 (5.5) 16 (4.8) 14 (4.2) 13 (3.9) 11 (3.3) 1 (3.) 8 (2.4) 7 (2.1) ALT, alanine aminotransferase; AST, aspartate aminotransferase. 2 (.6) 2 (.6) 4 (1.2) 2 (.6) 1 (.3) 1 (.3) 9 (5.6) 3 (1.9) 5 (3.1) 9 (5.6) 7 (4.3) 4 (2.5) 6 (3.7) 3 (1.9) 1 (.6) 3 (1.9) 1 (.6) 2 (1.2) 1 (.6) Kang ASCO GI 217
31 Avelumab (JAVELIN JPN) Ph 1b in GC/GEJ pts Irrespectively of PD-L1 status 1 st Line Maintenance (89 pts) 2 nd Line (62 pts) Avelumab 1 mg/kg IV Q2W Treatment-related adverse events Any grade: in 89 pts (58.9%) Infusion-related reaction (12.6%) and fatigue (1.6%) G3: in 15 pts (9.9%) fatigue, asthenia, increased GGT, thrombocytopenia, and anemia 1 treatment-related death (hepatic failure/autoimmune hepatitis) ORR % (95% CI) mpfs w (95% CI) 2L (n = 22) Mn (n = 52) PD-L1+ (n = 11) PD-L1 (n = 11) PD-L1+ (n = 2) PD-L1 (n = 32) (2.3, 51.8) (.2, 41.3) (1.2, 31.7) (.1, 16.2) (5.4, 18.) (4.1, 21.9) (6., 24.1) (5.7, 14.1) Chung ASCO 216
32 Ipilimumab Mn (Ph II Trial) 1st Line Ttx Ipi 1 mg/kg Q3W x4 Ipi 1 mg/kg Q12W x3y BSC ( 8% chemotherapy) 1ary EP: irpfs The study was stopped post-interim analysis 143 pts screened Treatment-related adverse events occurred in 41/57 (72%) of ipi pts and 25/45 (56%) pts on active BSC Pruritus (32%), diarrhea (25%), fatigue (23%), and rash (18%) Moehler ASCO 216
33 Ipilimumab Mn (Ph II Trial) irpfs similar between arms (HR=1.44, p=.97) median OS for both arms 1 yr Median irpfs (95% CI) Ipi 2.92 ( ) BSC 4.9 ( ) When the immune system reacts, it reacts well, potentially even in re-introduction or 2nd L Early progressors lost Moehler ASCO 216
34 Other immune checkpoints & combination strategies Atezolizumab, durvalumab Combined strategies Anti-angiogenic agents Immune response Vasculature normalization Interstitial pressure Perfusion Adhesion molecules Preserve endothelial cell anergy Availability of glucose, amino acids and oxygen Lymphocyte infiltration T-cell access and function Manning Clin Ca Res 27 Hodi Cancer Immunol Res 214 Sznol J Clin Oncol 215 (suppl)
35 Combined strategies Immunotherapy + anti-angiogenesis 1 Ph 1a/b trial (refractory gastric and GEJ cancer) Pembrolizumab + Ramucirumab No new safety signals and preliminary efficacy data has been reported Immunotherapy + palliative radiotherapy (Abscopal Effect) 2 Phase 2 trial (refractory esophageal, gastric and GEJ cancer) Pembrolizumab + palliative radiotherapy (3 Gy on 1 ary tumor or single metastasis) Pembrolizumab until PD 1 ary End Point: biomarkers of immune response and ORR (RECIST1.1, irrecist) 1. Chau ASCO GI 217; 2. Chao ASCO GI 217
36 Combined strategies Immunotherapy + Targeted Agents With anti-her2 agents 1 Phase 1b/2 trial (HER2-pos gastric and GEJ cancer) Pembrolizumab + Margetuximab 1 ary End Point: ORR (RECIST v1.1 and irecist) and DoR With anti-mmp9 agents 2 Phase 3 trial (2 nd /3 rd line gastric and GEJ cancer) Nivolumab +/- GS ary End Point: ORR (RECIST v1.1) 1. Catenacci ASCO GI 217; 2. NCT
37 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
38 Change from baseline SPD (%) Change from baseline SPD (%) Change from baseline SPD (%) Change from baseline SPD (%) Identifying patterns of response Response in baseline lesions Relative day from first dose SPD (mm 2 ) Stable disease with slow, steady decline in total tumor volume Relative day from date of first dose SPD (mm 2 ) Response after initial increase in total tumor volume N Relative day from date of first dose SPD (mm 2 ) Reduction in total tumor burden after appearance of new lesions 21 N N N N N N Relative day from date of first dose SPD (mm 2 ) Wolchok Clin Cancer Res 29
39 Managing immune-related AEs Myositis Myasthenia Gravis Hypothyroidism Pneumonitis Autoimmune hepatitis Elevated transaminases Pancreatitis Colitis - duodenitis Type 1 diabetes mellitus Rash Melero Clin Cancer Res 213
40 Outline The Immune System Rational to develop immunotherapy in GC/GEJ First evidence of efficacy Challenges Conclusions
41 Conclusions The immune system plays an important role in GC tumorigenesis (specifically in some subtypes) Checkpoint inhibitors have shown encouraging preliminary efficacy Efforts to identify predictive biomarkers have already begun, as well as to identify the immune-pattern of response and the management of the related Aes The huge amount of current prospective clinical trials will validate their true role 1. Seagal ASCO 216
42 Ongoing phase II/III clinical trials Adjuvant CA Ph 3 GEJ Nivolumab vs placebo after CRT and surgery MK Ph 3 PDL1 + Neoadjuvant NCT Ph 1b/2 GEJ Pembrolizumab Chemoradiotherapy (carboplatin and paclitaxel) CA Ph 1 GEJ/GC EBV+ Nivolumab vs Ipilimumab + Nivolumab First Line CDDP/FU (or CPC) vs CDDP/FU + Pembrolizumab vs Pembro monotherapy EMR-17-7 Ph 3 All (HER2 -) Avelumab (maintenance after XELOX/FOLFOX) CA Ph 3 All (HER2 -) Nivolumab + Ipilimumab vs FOLFOX/XELOX Second Line and beyond MK Ph 3 All Pembrolizumab vs paclitaxel GS-US Ph 2 All Nivolumab +/- GS-5745 EMR-17-8 Ph 2 PDL1 + Avelumab vs investigator s choice CA Ph 1 EBV + Nivolumab
43 Ongoing Phase I Clinical Trials ID Ph Strategy Indication Status NCT I Pembrolizumab plus Ramucirumab Specific cohort, 2 nd or 3 rd Line Recruiting NCT Pembrolizumab in monotherapy or in Different lines, HER2- II (KEYNOTE 59) combination with CT neg Recruiting NCT I Pembrolizumab plus PEGPH2 Specific cohort, at least 2 nd Line Recruiting NCT Specific cohort, I Pembrolizumab (KEYNOTE 12) refractory setting Active, not recruiting NCT I Pembrolizumab plus PLX3397 Specific cohort, refractory setting Recruiting NCT I/II Pembrolizumab plus trastuzumab Specific cohort, HER2- positive Recruiting NCT I/II Pembrolizumab plus FOLFOX Specific cohort Recruiting NCT II Tremelimumab and/or durvalumab Refractory setting Recruiting NCT II Ipilimumab vs FU/BSC NCT I/II Nivolumab +/- ipilimumab Manteinance after 1 st Line Specific cohort, refractory setting Completed Recruiting NCT I Nivolumab Refractory setting Recruiting NCT I/II Nivolumab EBV-positive Recruiting NCT17724 I Avelumab Specific cohort, 3rd Line Recruiting NCT I Avelumab NCT I Atezolizumab montherapy or in combination with bevacizumab or CT 2nd and 3rd Line, Japanesse and Asian Basket Recruiting Recruiting NCT I Atezolizumab Basket Recruiting NCT I Atezolizumab and GDC-919 Specific cohort, refractory setting Recruiting
44 Muchas gracias!
Inmunoterapia en tumores digestivos no colorrectales
Inmunoterapia en tumores digestivos no colorrectales Santander, 13 de Julio del 2017 Maria Alsina, MD PhD Hospital Universitari Vall d Hebron Outline Introduction Hepatocarcinoma Pancreatic Cancer Gastric
More informationTumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla.
Tumores esófago-gástricos, tiene algo que decir la inmunoterapia? Dr. Fernando Rivera Herrero Hospital Universitario Marqués de Valdecilla. Santander Finantial disclosure Consultor: CELGENE Research fundings:
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationNOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO
NOVITA IN TEMA DI CARCINOMA GASTRICO ROSA BERENATO ONCOLOGIA MEDICA 1 FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI MILANO PROGRESS AGAINST METASTATIC GC OS in first-line palliative setting Little progress
More informationNew experimental targets for gastric cancer Andrés Cervantes
New experimental targets for gastric cancer Andrés Cervantes Professor of Medicine Outline Acquired capabilities of Cancer IGFR pathway PI3K-AKT-m-TOR pathway MET pathway FGFR pathway Check point inhibitors
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationHighlights STOMACH CANCER
UPDATES and NEWS from the Gastrointestinal Cancers Symposium in San Francisco Roma, 10-11 Febbraio 2017 Highlights STOMACH CANCER Lorenzo Fornaro, MD Unit of Medical Oncology 2 Azienda Ospedaliero-Universitaria
More informationImmunotherapy for Upper GI Cancers
Immunotherapy for Upper GI Cancers Esophageal Adenocarcinoma GE Junction Adeno Gastric Carcinoma Ahmed Zakari MD Medical Director of GI Cancer Program, Florida Hospital Cancer Institute Associate Professor
More informationESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT
ESMO 2017, Madrid, Spain Dr. Loredana Vecchione Charite Comprehensive Cancer Center, Berlin HIGHLIGHTS ON CANCERS OF THE UPPER GI TRACT DOCETAXEL, OXALIPLATIN AND FLUOROURACIL/LEUCOVORIN (FLOT) FOR RESECTABLE
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationUpdate on the development of immune checkpoint inhibitors
Update on the development of immune checkpoint inhibitors Jean-Pascal Machiels Department of Medical Oncology Laboratory of Medical Oncology Cliniques universitaires Saint-Luc Université catholique de
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Royal Marsden Hospital ESMO Colorectal Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role Servier, Celgene, BMS, Five
More informationBristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA
3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationInmunoterapia en Tumores Diges1vos
Inmunoterapia en Tumores Diges1vos Santander, 14 y 15 Julio 2016 Maria Alsina, MD Hospital Universitari Vall d Hebron Outline The Immune System Immunotherapy in GI Tumors Gastric Cancer Colorectal Cancer
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationUpdates and best practices in the management of gastric cancer
Updates and best practices in the management of gastric cancer Olatunji B. Alese, MD Gastrointestinal Oncology, Winship Cancer Institute of Emory University July 28, 2017 1 Incidence 3rd leading cause
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationImmunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg
Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationMelanoma: Immune checkpoints
ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationImmunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France
Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France Overall Survival for Metastatic Melanoma Proportion Alive 1.0 0.8 0.6 0.4 0.2 Survival data
More informationIl ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento
Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCurrent Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology
Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationImmunotherapy in non-small cell lung cancer
Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationImmunotherapy on the Horizon
Immunotherapy on the Horizon Andrew L. Coveler Assistant Professor of Medicine, Division of Oncology University of Washington Assistant Member Fred Hutchinson Cancer Research Center Image: NASA.gov 1 2
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationMELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona
MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced NSCLC
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationPrinciples and Application of Immunotherapy for Cancer: Advanced Melanoma
In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More informationInmunoterapia en el carcinoma de Células de Merkel. Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona
Inmunoterapia en el carcinoma de Células de Merkel Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Epidemiology Merkel cell carcinoma is an uncommon neuroendocrine carcinoma that mostly arises
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationImmune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes
Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationGetting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers
Getting to the Bottom of Treatment: An Update in the Management of Esophagogastric Cancers Disclosures None Cindy L. O Bryant, PharmD, BCOP, FCCP, FHOPA Professor, University of Colorado Skaggs School
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationImmunotherapy in lung cancer. Saurabh maji
Immunotherapy in lung cancer Saurabh maji Worldwide, lung cancer is the most common cause of cancerrelated deaths Small cell lung cancer (SCLC) presents with widespread disease at the time of diagnosis,
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationNews from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital
News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationESMO 2016 * Investor Meeting October 9, *European Society of Medical Oncology, October 7-11, 2016 ESMO 2016 NOT FOR PRODUCT PROMOTIONAL USE
ESMO 2016 * Investor Meeting October 9, 2016 *European Society of Medical Oncology, October 7-11, 2016 1 Forward-Looking Information During this meeting, we will make statements about the Company s future
More information